Enabling better pharmaceuticals
PolyTherics provides site-specific conjugation technologies and novel polymers to enable the development of better biopharmaceutical products.
Technology toolbox
Our range of technologies and polymers for site specific conjugation of cytotoxic drugs and PEGylation of proteins, peptides and antibodies provides flexibility to modify your therapeutic agent to create a more homogeneous and stable product with the desired clinical benefit.
Find out more
Collaboration options
We offer product-specific licences for the application of our technologies to enable the development of better biopharmaceuticals and can evaluate your therapeutic product in combination with our technologies or provide our reagents to you to evaluate.
Find out more
Antibody drug conjugates
Our site-specific conjugation technologies have the flexibility to link your therapeutic or diagnostic payload (e.g. cytotoxic drug, toxin or radionuclide) to virtually any protein, peptide or antibody that binds to a specific target to create a protein or antibody drug conjugate (ADC).
Find out more
PK/PD Optimisation
The conjugation of poly(ethylene glycol) (PEG) to a therapeutically active molecule can extend its half-life and thus its duration of action. We have a range of technologies for the site-specific conjugation of PEG (PEGylation), or other polymers, to proteins and peptides.
New product formats
Our site-specific conjugation technologies can be used to rapidly produce a range of novel product candidates by linking two versions of the same protein or proteins with different binding entities together, including antibody fragments, alternative scaffolds, and peptides.
Targeted delivery
PolyTherics’ novel glycopolymer (GlycoPol™) is available for the delivery of a pharmacologically active agent to cells that differentially express a binding protein or sugar receptor that can be targeted with a specific mono-, di- or polysaccharide.
Find out more
